SABCS 2016: Extended Letrozole Therapy May Have Limited Benefits

Data presented at the San Antonio Breast Cancer Symposium showed that five additional years of the aromatase inhibitor (AI) therapy letrozole (Femara) following an initial five years of AI-based adjuvant hormone therapy did not significantly improve survival outcomes in postmenopausal women with early-stage HR-positive breast cancer. The additional five years did improve some outcomes related to recurrence.

Read More

Increasing Awareness of Breast Cancer Health Disparities

This month is Breast Cancer Awareness Month, a type of cancer against which we have made much progress. However, a recent report from the Centers for Disease Control and Prevention (CDC) highlights that the progress we are making has not been uniform for all segments of the population.

Read More